Key Details
Price
$76.00Annual ROE
12.50%Beta
0.40Events Calendar
Next earnings date:
Feb 13, 2025Recent quarterly earnings:
Oct 29, 2024Recent annual earnings:
Feb 13, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Sept 01, 2000Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Levi & Korsinsky has informed investors that it is starting an investigation into Incyte Corporation (NASDAQ:INCY) for potential breaches of federal securities laws. This comes after Incyte announced on November 18, 2024, that it would stop enrolling participants in the Phase 2 trial of its drug INCB000262 for chronic spontaneous urticaria (CSU) because of some concerning preclinical toxicology results.
Incyte (INCY) shared its earnings report 30 days ago. What can we expect for the stock moving forward?
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) has announced that it will present at Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024, at 8:00 a.m. The presentation will be available to watch live online at Investor.Incyte.com and can be replayed for 30 days afterward. Incyte is a global biopharmaceutical company dedicated to finding solutions for patients with unmet medical needs through scientific research and development.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH24--Incyte will highlight new findings, including a late-breaking oral presentation on Tafasitamab for Follicular Lymphoma, at the 2024 ASH Annual Meeting.
Levi & Korsinsky has informed investors that it is starting an investigation into Incyte Corporation (NASDAQ:INCY) for potential breaches of federal securities laws. On November 18, 2024, Incyte announced that it would stop enrolling participants in the Phase 2 trial of its drug INCB000262 for chronic spontaneous urticaria (CSU) because of some concerning preclinical toxicology results.
Levi & Korsinsky has informed investors that it is starting an investigation into Incyte Corporation (NASDAQ:INCY) for potential breaches of federal securities laws. This comes after Incyte announced on November 18, 2024, that it will stop enrolling participants in the Phase 2 trial of its drug INCB000262 for chronic spontaneous urticaria (CSU) because of some concerning preclinical toxicology results.
INCY has halted enrollment in the phase II study of MRGPRX2 for CSU after finding some concerning preclinical toxicology results in their in vivo tests.
Incyte (INCY) was the biggest loser in the S&P 500 on Tuesday afternoon after the pharmaceutical company announced it would halt the development of one drug and pause the enrollment for another study.
The biopharmaceutical company shared unsatisfactory news regarding two of its research studies.
On Monday, Incyte Corporation (INCY) announced that it will stop enrolling new participants in the current Phase 2 study of MRGPRX2 (INCB000262) for chronic spontaneous urticaria (CSU).
FAQ
- What is the primary business of Incyte?
- What is the ticker symbol for Incyte?
- Does Incyte pay dividends?
- What sector is Incyte in?
- What industry is Incyte in?
- What country is Incyte based in?
- When did Incyte go public?
- Is Incyte in the S&P 500?
- Is Incyte in the NASDAQ 100?
- Is Incyte in the Dow Jones?
- When was Incyte's last earnings report?
- When does Incyte report earnings?
- Should I buy Incyte stock now?